Company Profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Latest News
PINK vs. XLV: How Do These Two Health Care ETFs Match Up?
A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks In
Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
How to Build $4,000 a Month in Dividend Income Without Selling a Single Share
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.jnj.com |
| Audit Risk | 4 |
| Board Risk | 7 |
| Overall Risk | 4 |
| Market Cap | 634.77B |
| Trailing P/E | 30.59 |
| Forward P/E | 20.53 |
| Dividend Rate | 5.36 |
| Dividend Yield | 2.03% |
| Trailing Annual Div. Rate | 5.24 |
| Trailing Annual Div. Yield | 2.02% |
| Trailing EPS | 8.61 |
| Forward EPS | 12.83 |
| Book Value | 33.74 |
| Price-to-Book | 7.81 |
| Enterprise-to-Revenue | 6.77 |
| Enterprise-to-EBITDA | 19.01 |
| Short Ratio | 3.04 |
| Ex-Dividend Date | 08/25/2026 |
| Dividend Date | 09/08/2026 |
| Earnings Date | 10/13/2026 |
| Earnings Call Date | 07/15/2026 |
| Earnings Average | 3.05 |
| Earnings Low | 2.95 |
| Earnings High | 3.18 |
| Revenue Average | 25.32B |
| Revenue Low | 25.04B |
| Revenue High | 25.55B |